Obesity-induced increase of CYP2E1 activity and its effect on disposition kinetics of chlorzoxazone in Zucker rats by Khemawoot Phisit et al.
Obesity-induced increase of CYP2E1 activity
and its effect on disposition kinetics of
chlorzoxazone in Zucker rats


























Obesity-induced increase of CYP2E1 activity and its effect on
disposition kinetics of chlorzoxazone in Zucker rats
b i o c h em i c a l p h a rm a co l o g y x x x ( 2 0 0 6 ) x x x – x x x
avai lab le at www.sc iencedi rec t .com
journal homepage: www.e lsev ier .com/ locate /b iochempharmO
Phisit Khemawoot, Koichi Yokogawa, Tsutomu Shimada, Ken-ichi Miyamoto *






a r t i c l e i n f o
Article history:
Received 8 August 2006

















a b s t r a c t
This study was designed to investigate the induction of CYP2E1 in obese Zucker rats and its
effect on the disposition kinetics of chlorzoxazone (CZX). CZX 20 mg/kgwas administered to
three groups of rats: normal Zucker rats fed a normal diet (ND), normal Zucker rats fed a
high-fat diet (HF), and genetically obese Zucker rats fed a normal diet (OB). The values of the
area under the plasma concentration–time curve from 0 to 1 (AUC1) of CZX were in the
order of ND > HF > OB rats. The AUC1 values of total 6-hydroxychlorzoxazone (6OHCZX-T),
which is considered to be a CYP2E1metabolicmarker, were in the opposite order. The values
of the AUC1 ratio (6OHCZX–T/CZX) in ND, HF and OB rats were approximately 0.2, 0.3 and
0.4, respectively. The CZX concentration in fat was much higher than the concentrations in
plasma, liver and kidney in all groups. Induction of CYP2E1 protein was greater in both liver
and fat of OB rats than in those of HF rats. Microsomal activity of CYP2E1 in liver and fat was
also in the order of OB > HF > NM rats. These results suggest that CYP2E1may be induced in
liver and fat of obese patients, thereby potentially altering the disposition kinetics of not
only CZX, but also other lipophilic drugs metabolized by CYP2E1.
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92[3,4]. The overfed normal rat can also mimic physiological
aspects of severe obesity in humans, such as hypercholester-
olemia, hyperinsulinemia, etc. [5,6].
Changes in physiological status, such as obesity and
hypercholesterolemia, can modulate the metabolic activity of
CYP2E1 [7–9]. Interestingly, CYP2E1 is a ubiquitous enzyme that
is distributed in various organs of animals, but obesity-related
increase of CYP2E1 activity is well documented only in liver.
There are several reports that the hydroxylation of chlorzox-
azone (CZX) can be used as an indicator of CYP2E1 activity both
in vivo and in vitro [10,11]. CZX is a muscle relaxant that
primarily undergoes hydroxylation, catalyzed mainly by
CYP2E1, to 6-hydroxychlorzoxazone (6OHCZX),which is rapidly
glucuronidated and excreted in urine [12,13]. CZX is lipophilic
[14], and so may be a suitable probe to examine the activity of
CYP2E1 in various tissues of obese animals.
This study was therefore designed to examine the induc-
tion of CYP2E1 in genetically obese Zucker rats fed a normal
diet (OB) and its effect on the disposition kinetics of CZX and
its metabolite 6OHCZX in liver, kidney and fat, compared with
those in normal Zucker rats fed a high-fat diet (HF) and normal







































2. Materials and methods
2.1. Materials
CZX and 6OHCZXwere purchased fromSigma–Aldrich Inc. (St.
Louis, MO). High-fat diet (LABO H Standard1) and normal diet
(LABO MR Stock1) were purchased from Nosan Corp.
(Yokohama, Japan). The high-fat diet contained 8.6% (w/w)
fat (total energy 346.7 kcal/100 g), while the normal diet
contained 4.1% (w/w) fat (total energy 259.2 kcal/100 g).
2.2. Animal treatment
Male 8-week-old Zucker (+/+) rats and genetically obese
Zucker ( fa/fa) rats were purchased from Japan SLC Inc.
(Toyama, Japan). The rats were divided into three groups:
normal Zucker (+/+) rats fedwithnormal diet (ND rats), normal
Zucker (+/+) rats fedwith high-fat diet (HF rats) and genetically
obese Zucker ( fa/fa) rats fed with normal diet (OB rats). The
animals were housed for 3 months in a climate- and light-
controlled environment with free access to water and the
designated food. All animal procedures were in accordance
with the standards set forth in the guidelines for the care and
use of laboratory animals at the Takara-machi Campus of
Kanazawa University.
2.3. Disposition kinetic of CZX
CZX (20 mg) was dissolved in 400 ml of 0.5N NaOH and diluted
with 600 ml of normal saline solution (20 mg/ml). This solution
was administered to rats at a dose of 20 mg/kg by i.v.
administration over 2 min via a lateral tail vein. Then,
approximately 0.2–0.5 ml of blood was collected from the tail
vein on the other side at 0.033, 0.083, 0.25, 0.5, 1, 2, 4, and 8 h
after completion of the administration of CZX. The blood was
centrifuged at 3000  g for 10 min, and the plasma wasPlease cite this article as: Phisit Khemawoot et al., Obesity-induced in





collected. Some rats were killed by decapitation at 4 h after
CZX administration, and the liver, kidney and abdominal fat
were quickly excised, rinsed well with ice-cold saline, blotted
dry, and weighed. Each tissue sample was homogenized with
normal saline and stored at 80 8C until analysis.
2.4. Sample preparation
The concentrations of CZX and 6OHCZX in biological samples
were analyzed as unchanged and glucuronidated fractions.
The assay of glucuronidated CZX and 6OHCZX was performed
according to Frye and Stiff [15] with slight modifications.
Briefly, a 100 ml sample of plasma or tissue homogenate was
added to 300 ml of 0.2 M phosphate buffer (pH 6.5) containing
500 units of b-glucuronidase. The mixture was incubated at
37 8C with shaking for 2 h, and then the reaction was stopped
by adding 100 ml of acetonitrile containing phenacetin (1 mg) as
an internal standard for HPLC analysis.
2.5. HPLC assay of CZX and 6OHCZX
To a 100 ml of sample solution was added 5 ml of diethyl ether,
then the mixture was shaken vigorously for 10 min, and
centrifuged at 3000  g for 10 min. The ether layer was
transferred to another tube for evaporation in a vacuum
centrifugal concentrator. In the case of adipose tissue, reverse
phase extraction from the oil phase of homogenated samples
was done by adding 0.5N NaOH to the samples and mixing.
The aqueous phase was collected and titrated with an equal
amount of 0.5N HCl. Next, diethyl ether (5 ml) was added to
extract CZX and 6OHCZX fromaqueous phase, and the organic
solution was further processed as described above.
The residue from evaporationwas dissolved in 200 ml of the
mobile phase, and a 50 ml aliquot was injected into an HPLC
system (LC-9A, Shimadzu Co. Ltd., Kyoto, Japan) equipped
with a CAPCELL PAK C18 column, 1.5 mm i.d.  150 mm
(Shiseido Co. Ltd., Tokyo, Japan). The mobile phase consisted
of 25% (v/v) acetonitrile in 50 mMKH2PO4 (pH 4.0), pumped at a
rate of 0.1 ml/min. The absorbance was detected at wave-
lengths of 295 and 287 nm for 6OHCZX and CZX, respectively
[14,16]. The retention times of 6OHCZX, phenacetin and CZX
were approximately 5, 12 and 20 min, respectively. Linear
calibration curves (r > 0.999) were obtained for both com-
pounds in plasma over the concentration range from 1 to
150 mg/ml. The limits of detection were estimated to be
0.25 mg/ml for both CZX and 6OHCZX.
2.6. Reverse transcriptase polymerase chain reaction (RT-
PCR) assay
Total RNA was isolated from liver, kidney and fat with Isogen
(NipponGeneCo. Ltd., Toyama, Japan). EachRNAsample (1 mg)
was reversed-transcribed at 37 8C for 2 h, and the cDNA was
amplified with a Peltier Thermal Cycler PTC-100 (Bio-Rad
Laboratories Inc., Hercules, CA). The numbers of amplification
cycles were 30 for fat cDNA and 25 for cDNAs from other
tissues. PCR productswere evaluated by electrophoresis on 2%
(w/v) agarose gel stained with ethidium bromide, and
photographed under UV trans-illumination. The product size
was estimated by comparison with a 100 bp DNA laddercrease of CYP2E1 activity and its effect on disposition kinetics of
oi:10.1016/j.bcp.2006.09.006








































































(Takara Bio Inc., Shiga, Japan). Control reactions to verify the
absence of contaminants and genomic DNA were routinely
performed. Primers used for rat CYP2E1were 50-CTG ATT GGC
TGCGCACCCTGC-30 and 30-GAACAGGTCGGCCAAAGTCAC-
50 (363 bp), and those for rat b-actin were 50-TTC TACAATGAG
GTG CGT GTG GC-30 and 30-CTC CTA GCT CTT CTC CAG GGA
GGA-50 (456 bp). PCR was run under the following conditions:
initial denaturation at 94 8C for 3 min, repeated denaturation
at 94 8C for 45 s, followed with annealing at 66 8C for 45 s for
CYP2E1 and 67 8C for 45 s for b-actin, primer extension at 72 8C
for 45 s, and final extension at 72 8C for 3 min. The other
conditions for RT-PCR were as described previously [17].
2.7. Preparation of microsomes
Tissue microsomes were prepared according to Yokogawa
et al. [17] with slightmodifications. Liver, kidney or abdominal
fat was homogenized with phosphate buffer (50 mM K2HPO4
containing 0.1 mM EDTA, pH 7.4). The homogenate was
centrifuged at 10,000  g for 30 min, and then the supernatant
was recentrifuged at 100,000  g for 60 min. The microsomal
pellet was collected, and resuspended in an appropriate
volume of 50 mMTris–acetate buffer (pH 7.4) containing 1 mM
EDTA and 20% glycerol. The protein concentration of the
microsomal solution was determined with a protein assay kit
from Bio-Rad Laboratories Inc. (Hercules, CA).
2.8. Immunoblotting
Immunoblotting of the microsomes for CYP2E1 and b-actin
was carried out essentially as described by Yokogawa et al.
[18]. The microsomal protein was resolved by 10% SDS-PAGE,
and transferred to a polyvinylidene fluoride membrane or
Immobilon-P1 (Millipore Co., Bedford, MA). The membrane
was incubated with blocking buffer for 1 h (5%, w/v, non-fat
dried milk in PBS), followed with overnight incubation in a
2000-fold dilution of primary antibody (goat anti-rat CYP2E1
from Daiichi, Pure Chemicals Co., Ltd., Tokyo, Japan, and goat
anti-rat b-actin from Santa Cruz Biotechnology Inc., SantaUN
CO
R
Please cite this article as: Phisit Khemawoot et al., Obesity-induced in
chlorzoxazone in Zucker rats, Biochemical Pharmacology (2006), d




Body weight (g) 385  5.0
Liver (g) 5.94  0.42
Kidney (g) 2.11  0.08
Epididymal fat (g) 3.49  0.64
Biochemical data
Albumin (g/dl) 4.26  0.23
T-bilirubin (mg/dl) 0.057  0.006
T-cholesterol (mg/dl) 75  1.5
Creatinine (mg/dl) 0.29  0.02
AST (IU/l) 81  7.0
Cholinesterase (IU/l) >4






Cruz, CA). The membranes were then incubated with a 2000-
fold dilution of secondary antibody (rabbit anti-goat IgG from
Santa Cruz Biotechnology Inc., Santa Cruz, CA). The immu-
nopositive band was detected with an ECL chemilumines-
cence detection kit (Amersham Biosciences UK Ltd.,
Buckinghamshire, UK), and scanned with a Typhoon 9200
scanner (Amersham Biosciences Europe GmbH, Freiburg,
Germany).
2.9. Measurement of hydroxylation activity of microsomal
CYP2E1
The enzyme activity of microsomal CYP2E1 was determined
by the measurement of 6OHCZX formation according to
Chittur and Tracy [19], withminormodifications. Amixture of
the microsomal solution (equivalent to 0.4 mg protein) and
50 mM phosphate buffer (pH 7.4) containing 50 mM CZX and
1 mM NADPH (final, 200 ml) was incubated at 37 8C for
appropriate times. The reaction was stopped by adding
100 ml of acetonitrile containing phenacetin (1 mg) as an
internal standard for HPLC assay. The 6OHCZX formed was
extracted with diethyl ether and measured by HPLC as
described above.
2.10. Measurement of glucuronidation activity of
microsomal UGTs
The activity of UDP-glucuronosyltransferase (UGT) in
microsomes was measured colorimetrically in 0.15 M tris-
phosphate buffer pH 7.4 containing 0.8 mM p-nitrophenol
(PNP), 14 mM UDP glucuronic acid, 10 mM MgCl2, and 1 mg
microsomal protein [20]. The mixture (1.4 ml) was incubated
at 37 8C for 30 min, then the reaction was stopped by adding
5 ml of 0.2 M glycine buffer (pH 10.4). The disappearance of
PNP was quantified in terms of absorbance at 405 nm with a
UV–vis spectrophotometer. The microsomal activities for
glucuronidation of CZX and 6OHCZX were assayed similarly,
except that the disappearance of CZX and 6OHCZX was




410  17.3 480  8.3**
6.22  0.64 11.85  0.88**
2.13  0.14 2.23  0.12
4.35  1.12 12.74  1.63**
4.30  0.10 4.07  0.06
0.057  0.012 0.28  0.030**
81  2.1* 88  1.5**
0.30  0.02 0.31  0.01
79  3.1 83  6.6
>4 >4
e from ND rats at P < 0.05. **Significant difference from ND rats at















































Fig. 1 – Plasma concentration–time courses of CZX (closed
symbols) and 6OHCZX-T (open symbols) after an i.v.
administration of CZX (20 mg/kg) over 2 min in ND (*), HF
(&) and OB (~) rats. The concentration of CZX is shown as
unchanged fraction, while 6OHCZX is shown as total
6OHCZX (unchanged fraction plus glucuronidated
fraction). Each point and bar represents the mean + S.D. of
four rats. *Significant difference from ND rats at P < 0.05.
**Significant difference from ND rats at P < 0.01.2.11. Data analysis
The pharmacokinetic parameters were calculated according to
model-independentmomentanalysisasdescribedbyYamaoka
etal. [21]. ElectrophoregramsafterRT-PCRand immunopositive
bands were evaluated in arbitrary units by using NIH Image
software. Comparisons of numerical data among groups were
made by one-way ANOVA, with P < 0.05 as the criterion of a
significant difference. For each significant effect, a multiple
comparison testwas performedwith Scheffe’s test to verify the
difference between groups at P-values of 0.05 and 0.01, using
SPSS 101 from SPSS Inc. (Chicago, IL).UN
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a 204  14
T1/2 (h
1)b 1.67  0.18
MRT (h1)c 2.40  0.19
CLtot (1/h kg)
d 0.104  0.002
Vdss (1/h)
e 0.239  0.014
6OHCZX-T
AUC1 (mg/h ml) 41.2  4.7
Data were presented as mean  S.D. of four rats. *Significant differenc
P < 0.01.
a AUC from 0 to 1.
b Half life.
c Mean residence time.
d Total clearance.






3.1. Physical and biochemical data
Table 1 summarizes the physical data for ND, HF and OB rats.
The body, liver and epididymal fat weights of OB rats were
significantly higher than those of ND rats. The fat tissue
weight of HF rats, although slightly higher, was not signifi-
cantly different from that of ND rats. The value of total
bilirubin of OB rats was significantly higher than that of ND
rats, but liver function (AST) and kidney function (creatinine)
were unaffected. Total cholesterol was significantly increased
in HF rats and OB rats compared with normal rats.
3.2. Disposition kinetics of CZX
Fig. 1 shows the plasma concentration–time courses of CZX
and 6OHCZX after an i.v. administration of CZX 20 mg/kg in
ND, HF andOB rats. The plasma concentrations of CZX linearly
decreased in all cases, but the concentration at 8 h after
administration was in the order of ND > HF > OB rats. In this
figure, the concentration of 6OHCZX is presented as a total
value of 6OHCZX (6OHCZX-T), i.e., the sumof free 6OHCZX and
glucuronidated 6OHCZX, after the administration of CZX. The
amount of the glucuronide conjugate of CZX (CZX-G) was
negligible (data not shown). It was found that the plasma
concentration of 6OHCZX-T increased gradually and reached a
peak at about 2 h after administration. The peak concentration
of 6OHCZX-T in OB rats was significantly higher than that in
ND rats. Table 2 shows the pharmacokinetic parameters of
CZX and 6OHCZX-T after administration of CZX 20 mg/kg. In
OB rats, the AUC1, T1/2 and MRT values of CZX were
significantly smaller, while the CLtot and Vdss values of CZX
were significantly larger than those of ND rats. The pharma-
cokinetic parameters in HF rats were intermediate between
those in OB rats and ND rats. Moreover, the AUC1 values of
6OHCZX-T in HF and OB rats were significantly higher than
that of ND rats.crease of CYP2E1 activity and its effect on disposition kinetics of
oi:10.1016/j.bcp.2006.09.006
ter an i.v. administration of CZX 20mg/kg over 2 min
Rats
HF OB
181  12 155  21**
1.38  0.19 1.19  0.23*
2.30  0.28 2.00  0.17*
0.122  0.010* 0.145  0.013**
0.277  0.014** 0.285  0.016**
60.3  4.2** 71.6  5.9**








































Fig. 2 – Tissue and plasma concentrations of CZX and its
glucuronide (CZX-G) at 4 h after an i.v. administration of
CZX (20 mg/kg) over 2 min in ND ( ), HF ( ) and OB ( ) rats.
Each column and bar represents the mean + S.D. of four
rats. *Significant difference from ND rats at P < 0.05.
**Significant difference from ND rats at P < 0.01.
Fig. 4 – Effect of obesity on the expression of CYP2E1 mRNA
compared with b-actin in liver, kidney and fat of ND ( ), HF
( ) and OB ( ) rats. Each column and bar represents the
mean + S.D. of four rats. *Significant difference from ND
rats at P < 0.05. **Significant difference from ND rats at
P < 0.01.
RE
Fig. 2 shows the tissue concentration of CZX comparedwith
the plasma concentration at 4 h after the i.v. administration of
CZX. The CZX concentration in fat tissue was considerably
higher than those of plasma, kidney and liver. The concentra-
tion of CZX-G was higher in HF rats and OB rats than ND rats.
Fig. 3 shows the tissue concentrations of 6OHCZX and its
glucuronide in fat, liver and kidney at 4 h after the i.v.
administration of CZX. The concentrations of both 6OHCZX
and 6OHCZX-G in plasma and all tissues tended to be higher in
theHF rats andOB rats than those in theND rats. Interestingly,
the kidney concentrationwasmuchhigher than those of other
tissues, and the concentration of 6OHCZX-G in kidney of OB
rats was significantly higher than that of ND rats.
3.3. Expression of CYP isoform mRNAs and proteins
ThemRNA expression of CYP2E1 in liver of HF rats and OB rats
was only slightly higher than that in ND rats, whereas, the
relative expression of CYP2E1/b-actin in fat tissue fromHF rats
and OB rats was apparently higher than that in ND rats (Fig. 4).UN
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Fig. 3 – Tissue and plasma concentrations of 6OHCZX (6OH)
and its glucuronide (6OH-G) at 4 h after an i.v.
administration of CZX (20 mg/kg) over 2 min in ND ( ), HF
( ) and OB ( ) rats. Each column and bar represents the
mean + S.D. of four rats. *Significant difference from ND




The expression levels of CYP2E1 protein in the liver, kidney
and fat tissue were examined by immunoblot analysis. The
protein levels of CYP2E1 in the liver and fat of HF rats and OB
rats were conspicuously increased comparedwith those of ND
rats. Furthermore, the relative expression of CYP2E1/b-actin in
liver microsomes and fat microsomes of HF and OB rats was
significant higher than that in ND rats (Fig. 5).
3.4. In vitro CYP2E1 and UGTs activity
Fig. 6 shows the hydroxylation activity of microsomal CYP2E1
in terms of 6OHCZX formation from CZX, in various tissues
from the three groups of rats. The highest hydroxylation rate
was found in the liver compared with kidney and fat tissue.
The activities in liver and fat from HF rats and OB rats were
significantly higher than those in ND rats, whereas, no
difference was seen in the kidney.
Fig. 7 shows the glucuronidation activity of microsomal
UGTs in liver and kidney towards PNP, CZX and 6OHCZX. The
glucuronidation rates in the kidney of HF rats andOB ratswere
generally significantly higher than those in ND rats. The
glucuronidation activity in fat was negligible in all groups.
Interestingly, the glucuronidation of CZXwas verymuch lower
than that of 6OHCZX, although the enzyme activity in the liver










Zucker ( fa/fa) rats at 20 weeks of age showed markedly
increased body weight, accompanied with an enlarged liver
and increased epididymal fat, compared with Zucker (+/+)
rats. In contrast, Zucker (+/+) rats fed with high-fat diet (twice
the level in normal diet) for 12 weeks did not show any
significant physical or biochemical changes (Table 1).
CZX is well known to be a specific probe for CYP2E1, being
hydroxylated to 6OHCZX [10,11], which in turn is rapidly















































Fig. 5 – Effect of obesity on the content of CYP2E1 protein
compared with b-actin in liver, kidney and fat of ND ( ), HF
( ) and OB ( ) rats. Each column and bar represents the
mean + S.D. of three rats. *Significant difference from ND
rats at P < 0.05. **Significant difference from ND rats at
P < 0.01.
Fig. 7 – Effect of obesity on the glucuronidation activity of
microsomal UGTs in liver and kidney of ND ( ), HF ( ) and
OB ( ) rats. Each column and bar represents the
mean + S.D. of four rats. *Significant difference from ND
rats at P < 0.05. **Significant difference from ND rats at
P < 0.01.
R
indicator for determining CYP2E1 activity in vivo should be the
total amount of 6OHCZX generated after the administration of
CZX, as reported in Fig. 1 and Table 2. The limited sampling
time course of 8 h post-administration was contributed to the
detection limits of both CZX and 6OHCZX. Most of 6OHCZX in
biological samples were lower than the detection limit, and
some of CZX levels were under the linearity of calibration
curves at 12 h after administration of CZX. The administration
of CZX 20 mg/kg to OB rats afforded lower values of AUC1 and
T1/2 in serum as compared with those in ND rats, while the
values of CLtot and Vdss were significantly higher (Table 2).
Based on the Vdss and the tissue concentration of CZX (Fig. 2),
it appears that lipophilic substances, such as CZX, penetrate
well into the fat reservoirs of OB rats. The fat to plasma ratio of
CZX was two to four folds both at 1 and 4 h of tissue sampling
time, and theOB rats showed thehigher trendof accumulation
(data not shown for 1 h). Therefore, if CYP2E1 were not
induced in the fat of OB rats, it is likely that the elimination
rate of CZX would be delayed. However, the T1/2 of CZX in OB
rats was shorter than in ND rats, and further, the value ofUN
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Fig. 6 – Effect of obesity on the hydroxylation activity of
microsomal CYP2E1 in liver, kidney and fat of ND ( ), HF
( ) and OB ( ) rats. Each column and bar represents the
mean + S.D. of four rats. *Significant difference from ND
rats at P < 0.05. **Significant difference from ND rats at
P < 0.01.CT
ED
 P6OHCZX in fat higher than the plasma level (Fig. 3). It isunlikely that 6OHCZX from blood would accumulate in fat,because 6OHCZX is relatively hydrophilic and is rapidly
glucuronidated by UGTs located in smooth endoplasmic
reticulum, the same location as that of CYP2E1 [22]. Therefore,
the induction of CYP2E1 in fat, in addition to liver, may play a
pivotal role in determining the disposition kinetics of CZX in
obese rats. We also found that the AUC1 ratio of 6OHCZX–T/
CZX in HF rats and OB rats was 1.5–2 times higher than that in
ND rats, reflecting the increased total activity of CYP2E1 in rats
with obesity. Lucas et al. [7] reported that the 6OHCZX–T/CZX
ratio (0.4) in obese or hyperlipidemic patients was higher than
that (0.3) in normal subjects, in agreement with our finding.
These results suggest that obesity and feeding of a high-fat
diet can induce CYP2E1 activity in both humans and rats.
We found that both the protein content and activity of
CYP2E1were increased inmicrosomes of the liver fromHF rats
and OB rats, while there was no change in the kidney.
Kobayashi et al. [23] reported that CZX was extensively
metabolized in rat microsomes not only by CYP2E1, but also
by CYP1A2 and CYP3A. Therefore, we also examined the
mRNA expression and protein content of CYP1A2 and CYP3A,
but found that they were unaffected by obese status (data not
shown). Enriquez et al. and Irizar et al. [24,6] reported that
CYP2E is poorly expressed in obese Zucker rats, which is
consistent with our finding. However, Enriquez et al. [24]
reported that CZX hydroxylase activity and CYP2E1 protein
content were lower in Zucker ( fa/fa) rats than in lean (+/?)
littermates. There are various differences between their
experimental conditions and ours, but one of the most
important factors could be the influence of aging in obese
Zucker ( fa/fa) rats. Young obese Zucker ( fa/fa) rats do not
exhibit pathological conditions such as physical obesity,
insulin resistance, etc., and usually have a lower CYP2E1
activity than their lean littermates, whereas, after the
appearance of pathological symptoms at approximately 14–
16 weeks of age, expression of CYP2E1 is increased. Therefore,
we used Zucker ( fa/fa) rats at 20 weeks of age in our study,
when their pathological condition appeared to resemble that
of severe obesity in humans. The report by Enriquez et al. [24]crease of CYP2E1 activity and its effect on disposition kinetics of
oi:10.1016/j.bcp.2006.09.006












































































































did not mention the physical condition of either the lean or
obese Zucker rats, so that it is difficult to compare their
findings and ours. Interestingly, the CYP2E1 mRNA isoform
was expressed in fat tissue, and its expression level and
activitywere significantly higher in HF rats andOB rats than in
ND rats (Figs. 4–6). Yoshinari et al. [25] and Wan et al. [26]
reported that the expression levels of both CYP2E1 mRNA and
protein were increased in adipose tissue of fasting rats.
However, the amount of adipose tissue in fasting rats was
small, and so CYP2E1 in fasting animals may contribute little
to the pharmacokinetics of its substrates compared with the
situation in obese animals.
The hydroxylated metabolite of CZX (6OHCZX) has been
reported to be excreted in bile to only a small extent; rather it
undergoes rapid glucuronidation with subsequent excretion
of the conjugate in urine [13]. We found that the glucuronida-
tion activity in kidney microsomes was significantly higher in
HF rats and OB rats thanND rats (Fig. 7), and the concentration
of 6OHCZX glucuronide in the kidney was higher than that in
the liver (Fig. 3). Since there is no evidence that a specific UGT
subfamily in involved in glucuronide conjugation of CZX and
6OHCZX, we used PNP, a general marker for glucuronidation,
to confirm our results. The glucuronidation activity towards
PNP in kidneymicrosomes of HF and OB rats showed the same
trend as did the activity towards CZX and 6OHCZX. However,
the glucuronidation activity in liver microsomes was not
influenced by the high-fat diet or obese status, and was quite
different towards different substrates. This suggests the
presence of different UGTs isoforms in liver and kidney.
Further research will be required to identify the UGTs
isoform(s) responsible for 6OHCZX glucuronidation in tissues,
and the species that are affected by obese status.
In conclusion, CYP2E1 activity was induced in the liver and
fat tissues of obese animals, and glucuronidation activitywere
induced in the kidney. As a result, the disposition kinetics of
CZX was markedly changed in obesity, with an increase in
hydroxylation of CZX to form 6OHCZX, and an acceleration of
6OHCZX glucuronidation, resulting in rapid excretion in urine.
Other drugs that are metabolized by CYP2E1 and UGTs may
show similar changes of disposition kinetics in obese patients,
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